
Curenta
OperatingCurenta Enterprise Corp.
Healthcare · Technology · Laguna Hills, DE · Founded 2020
Reimaging the long-term pharmacy
Financials
FY2019–FY2020 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Pre-money — the valuation set before each round’s money came inBlue bars are the pre-money valuation the company stated for a priced round.
Fundraising history
Team
7 people
Licensed Pharmacist / MBA Maastricht School of Management A CA licensed pharmacist and MBA degree holder from MsM with 15+ years of experience in retail and Long-Term Care pharmacies & 5 years leading a 12 pharmacies-consortium focusing on long-term care, serving 15,000 beds.


PharmD / University of Health Sciences and Pharmacy in St. Louis A CA licensed PharmD and published clinical oncology researcher with pharmacy enterprise sales experience, focused on novel oncology drug-delivery systems. Utilizing his insight and experience in inpatient and outpatient pharmacy, Ryan is leading the team in building foundational business strategies with Long-Term Care facilities and Treatment Centers.

Amir Barsoum is the Founder and CEO of Vezeeta, a leading digital healthcare platform that offers patients a personalized, end-to-end healthcare experience from diagnosis to delivery of ongoing care and medications. Recognized as one of Fortune’s 40 under 40 global healthcare leaders in 2020, Amir helped pave the path for Vezeeta to become one of the fastest-growing health tech start-ups in the Middle East and Africa region and guided the expansion within the B2B landscape, with a growing footprint in North America, and Southeast Asia. Barsoum has helped shape the greater business community as an active angel investor and mentor for start-ups around the globe. He currently sits on the Board of three digital healthcare start-ups in the US, that focus on long-term care, revenue cycle management, and AI diagnostics. He is also a member of the Board of directors of Endeavor Egypt, and Entrepreneurs' Org, and offers guidance and consultations to major international institutions such as Bloomberg Health Council, Forbes Business Council, Endeavor, and MIT Legatum Centre. Prior to founding Vezeeta, he served as a Managing Consultant at McKinsey & Co. across Europe, and the Middle East region, and also held the position of Head of Strategic Planning at AstraZeneca. A pharmacist by education, Barsoum holds an MBA from MIT Sloan School of Management.


Mario specializes in M&A and international tax planning. During his time at Loyola Law School, Los Angeles, Mario was a member of the International Law Review and the Honors Tax Policy Colloquium. He also holds a B.B.A. from Emory University's Goizueta Business School in Finance, Strategy Management, and Entrepreneurship.
Names and titles as disclosed on SEC Form C, StartEngine. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
Filed 0 of 5 annual reports (FY2021–FY2025)
Missing: 2021, 2022, 2023, 2024, 2025
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.
